A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: Rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin

New England Journal of Medicine

Volumn 335, Issue 6, 1996, Pages 377-383

  Shafran, Stephen D ^a,k   Singer, Joel ^b   Zarowny, Donald P ^b   Phillips, Peter ^c   Salit, Irving ^d   Walmsley, Sharon L ^d   Fong, Ignatius W ^e   Gill, M John ^f   Rachlis, Anita R ^g   Lalonde, Richard G ^h   Fanning, Mary M ⁱ   Tsoukas, Christos M ^j  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Canadian HIV Trials Network   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j MONTREAL GENERAL HOSPITAL   (Canada)

^k UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; RIFABUTIN; RIFAMPICIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BACTEREMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; DRUG SCREENING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; UVEITIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; BACTEREMIA; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HUMANS; MALE; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RIFABUTIN; RIFAMPIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UVEITIS;

EID: 9344249534     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199608083350602     Document Type: Article

References (35)

1. Inderlied CB, Kemper CA, Bermudez LEM. The Mycobacterium avium complex. Clin Microbiol Rev 1993;6:266-310.
2. Benson CA, Ellncr JJ. Mycobacterium avium complex infection and AIDS: advances in theory and practice. Clin Infect Dis 1993;17:7-20.
3. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992;165: 1082-5.
4. Jacobson MA, Hopewell PC, Yajko DM, et al. Natural history of di-seminated Mycobacterium avium complex infection in AIDS, J Infect Dis 1991;164:994-8.
5. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T, Zidovudine Epidemiology Study Group. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am Rev Respir Dis 1992;146:285-9.
6. Hoy J, Mijch A, Sandland M, Grayson L, Lucas R, Dwyer B. Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients. J Infect Dis 1990;161:801-5.
7. Chiu J, Nussbaum J, Bozzette S, et al. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann Intern Med 1990;113:358-61.
8. Kemper CA, Meng T-C, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen: rifampin, ethambutol, clofazimine, and ciprofloxacin. Ann Intern Med 1992; 116:466-72.
9. Horsburgh CR Jr, Havlik JA, Ellis DA, et al. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis 1991;144:557-9.
10. Kerlikowske KM, Katz MH, Chan AK, Perez-Stable EJ. Antimycobacterial therapy for disseminated Mycobacterium avium complex infection in patients with acquired immunodeficiency syndrome. Arch Intern Med 1992;152:813-7.
11. Horsburgh CR Jr, Metchock B, Gordon SM, Havlik JA Jr, McGowan JE Jr, Thompson SE III. Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease. J Infect Dis 1994; 170:573-7.
12. Flegg PJ, Laing RBS, Lee C, et al. Disseminated disease due to Mycobacterium avium complex in AIDS. Q J Med 1995;88:617-26.
13. Chin DP, Reingold AL, Stone EN, et al. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients - a prospective study. J Infect Dis 1994;170:578-84.
14. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, doubleblind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121:905-11.
15. Heifets L, Mor N, Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993; 37:2364-70.
16. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-33.
17. Sullam PM, Gordin FM, Wynne BA, Rifabutin Treatment Group. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. Clin Infect Dis 1994;19:84-6.
18. Dautzenberg B, Ruf B, Esposito R, et al. Rifabutin vs placebo in combination therapy for the treatment of disseminated MAC in HIV+ patients. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fla., October 4-7, 1994. Washington, D.C.: American Society for Microbiology, 1994:6. abstract.
19. Kemper CA, Havlir D, Haghighat D, et al. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis 1994;170:157-64.
20. Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1332-8.
21. Ellner JJ, Goldberger MJ, Parenti DM. Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. J Infect Dis 1991; 163:1326-35.
22. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-56.
23. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection. Med Care 1991;29:786-98.
24. Salfinger M, Stool EW, Piot D, Heifets L. Comparison of three methods for recovery of Mycobacterium avium complex from blood specimens. J Clin Microbiol 1988;26:1225-6.
25. Shafran SD, Deschênes J, Miller M, Phillips P, Toma E. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. N Engl J Med 1994;330:438-9.
26. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer, 1980. (IARC scientific publications no. 32.)
27. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
28. Shafran SD, Singer J, MAC Study Group. Uveitis in AIDS patients with MAC decreases markedly at lower rifabutin doses in combination with ethambutol and clarithromycin. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-20, 1995. Washington, D.C.: American Society for Microbiology, 1995:242. abstract.
29. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1993;43(RR-9):14-20.
30. May T, Brel F, Beuscart C, et al. A French randomized open trial of 2 clarithromycin combination therapies for MAC bacteremia: first results. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-20, 1995. Washington, D.C.: American Society for Microbiology, 1995:11. abstract.
31. Chaisson RE, Benson CA, Dube M, et al. Clarithromycin therapy for disseminated Mycobacterium avium-complex (MAC) in AIDS. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif., October 10-14, 1992. Washington, D.C.: American Society for Microbiology, 1992:259. abstract.
32. Cohn DL, Fisher E, Franchino B, et al. Comparison of two doses of clarithromycin in a randomized trial of four 3-drug regimens for treatment of disseminated Mycobacterium avium complex disease in AIDS: excess mortality associated with high-dose clarithromycin. Presented at the 11 th International Conference on AIDS, Vancouver, B.C., July 7-12, 1996. abstract.
33. DATRI 001 Study Group. Clarithromycin (CL) plus rifabutin (RFB) for MAC prophylaxis: evidence for drug interaction. In: Abstracts of the First National Conference on Human Retroviruses and Related Infections, December 12-16, 1993. Washington, D.C.: American Society for Microbiology, 1994. abstract.
34. Idem. Coadministration of clarithromycin (CL) alters the concentration-time profile of rifabutin (RFB). In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fla., October 4-7, 1994. Washington, D.C.: American Society for Microbiology, 1994:3. abstract.
35. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995;171:747-50.